This essay has been submitted by a student. This is not an example of the work written by our professional essay writers.
Somatic mutations producing oncogenes or affecting the functions of tumour suppressor genes, give rise to cancers characterised by uncontrolled proliferation and invasion[89,91]. With the better understanding of the malignant transformation of cells, it has been easy to elucidate that tumour progression is a multistep process involving several defined events common to cancer cells[89,90]. Genes controlling cell cycle events, limit cell multiplication by activating anti-proliferative mechanisms, leading to arrest of cell cycle or apoptosis. Mutations of these genes lead to autonomous cell growth. This, alongwith metastasis adds more aggression to the armoury of cancer. In the race of finding medical arms and ammunitions to kill cancer, Science discovered a very crucial gene in the body, later named as, 'TP53 gene'. Emergence of TP53 gene provided, a whole new arsenal to combat cancer. The p53 protein, coded by TP53 gene, is an inducible transcription factor that plays multiple antiproliferative roles in response to exposure to DNA damaging stress. In a physiological context, status of p53 controls the sensitivity of cells to environmental mutagens. In a pathological context, the status of p53 is considered as a key factor in the response of cancer cells towards cyto-toxic therapies. Thus, p53 functions for the genetic homeostasis of the cells exposed to mutagens.
DISCOVERY AND HISTORY
In1979,Â L. Crawford,Â D. Lane, A. Levine, andÂ L. Old, identified p53. In 1982, Peter Chumakov was the first to clone theÂ TP53Â gene from mouse , while, the humanÂ TP53Â gene was cloned in 1984Â . It was hypothesized to exist as the target of theÂ SV40Â virus, a strain that induced development of tumors. Initially presumed to be anÂ oncogene, its character as aÂ tumor suppressor geneÂ was finally revealed in 1989 by B. Vogelstein. In 1993, p53 was votedÂ molecule of the yearÂ byÂ ScienceÂ magazine. In the same year, Wafik El-Deiry, working with Bert Vogelstein at Johns Hopkins University discovered that a gene, p21(WAF1), was directly,regulated by p53. This work provided a molecular mechanism by which mammalian cells undergo growth arrest when damaged. Binding of the p53 protein to the major oncogenic protein of SV40, strongly suggested that it was aÂ downstreamÂ effector of the large T-antigen pathway. The interpretation was consistent as high levels of expression of p53 was found in many cancers and so p53 was originally believed to be an Oncogene. In 1989, during a search for a putativeÂ tumor suppressor geneÂ onÂ chromosomeÂ 17p, p53 containing region came into focus. Researchers applied a "two-hit" test to distinguish whether a mutant gene is an oncogene or a tumor suppressor gene. The logic behind this "two-hit" test being, if both copies of the gene are altered, it is likely to be a tumor suppressor gene; if only one copy is altered, it is more likely to be an oncogene. When p53 went through this test, the results were very astonishing. The majority of colorectal tumors were surprisingly found to have subtle mutations of p53, generally a singleÂ base substitutionÂ (such as C to T) resulting in a newÂ amino acidÂ (BakerÂ et al. 1989). Also, virtually in all cases, both copies of p53 were mutated. One copy was generally altered by aÂ baseÂ substitution,Â while the other was often completely deleted from the cell. This result was expected for a tumor suppressor gene, and not for an oncogene. This "two-hit" test was later applied to many other tumor types and every-time a similar result was found (NigroÂ et al. 1989). Thus, bringing p53 into the center stage of human tumor research, and providing with an evidence that p53 was actually a tumor suppressor gene. Subsequent findings concluded that, patients with inherited mutations of p53 were predisposed to diverse tumor types (MalkinÂ et al. 1990, SrivastavaÂ et al. 1990). Studies have demonstrated that p53 is the most frequently mutated gene in human tumors than any other gene in theÂ genome.
The name 'p53' comes from the apparentÂ molecular mass of the protein. OnÂ SDS-PAGE, it runs as a 53-kilodaltonÂ (kDa) protein, but, based on calculations from itsÂ amino acidÂ residues, p53's molecular mass is actually only 43.7 kDa. This difference in molecular mass is due to the high number ofÂ prolineÂ residues in the protein, which slows its migration onÂ SDS-PAGE, thus making it appear heavier than it actually is.Â This effect is observed with p53 from other species too, including humans, rodents, frogs, and fish.
UniProt name: CellularÂ tumor antigenÂ p53
Transformation-related protein 53 (TRP53)
Tumor suppressor p53
In humans, theÂ TP53Â gene is located on the short arm ofÂ chromosome 17.Â Human p53 is a nuclear phosphoprotein of molecular weight- 53 kDa, encoded by a 20-Kb gene containing 11 exons and 10 introns. The coding sequence containing five regions shows a high degree of conservation in vertebrates, predominantly in exons 2, 5, 6, 7 and 8, but the sequences found in invertebrates show only distant resemblance to mammalian TP53. In humans, a commonÂ polymorphismÂ involving the substitution of anÂ arginineÂ for aÂ prolineÂ atÂ codonÂ position 72, indicates a possible cancer susceptibility, however, the results have been controversial. For instance, a meta-analysis from 2009 failed to show a link for cervical cancer, while, a 2011 study found that theÂ TP53Â proline mutation had a profound effect on pancreatic cancer risk among males. [14,15]Â A study of an Arab women found that proline homozygosity atÂ TP53Â codon 72 is linked with a decreased risk for breast cancer.Â A 2011 study concluded that, TP53Â codon 72 polymorphism was associated with an increased risk for lung cancer. In 2011, meta-analyses studies indicated that no significant associations existed betweenÂ TP53Â codon 72 polymorphisms and both colorectal cancer riskÂ and endometrial cancer risk. [18, 19]
Human p53 is 393Â amino acidsÂ long and has sevenÂ domains:
An acidicÂ N-terminusÂ Transcription Activation Domain (TAD), also known as Activation Domain 1 (AD1) [residues 1-42], activatesÂ transcription factors. The N-terminus contains two complementary transcriptional activation domains, with a major one at residues 1-42 and a minor one at residues 55-75, specifically involved in the regulation of several pro-apoptotic genes.
Activation Domain 2 (AD2) [residues 43-63] is important forÂ apoptoticÂ activity.
ProlineÂ rich domain [residues 64-92] is important for the apoptotic activity of p53.
CentralÂ DNA-Binding core Domain (DBD) [residues 102-292], containing one zinc atom and severalÂ arginineÂ amino acids, is responsible for binding the p53 co-repressorÂ LMO3.
Nuclear localization signaling domain[residues 316-325].
homo-oligomerisation domain (OD): residues 307-355. Tetramerization is essential for the activity of p53Â in vivo.
C-terminal [residues 356-393]Â is involved in downregulation of DNA binding of the central domain.
A tandem of nine-amino-acid transactivation domains (9aaTAD) was identified in the AD1 and AD2 regions of transcription factor p53.Â KO mutationsÂ and position for p53 interaction withÂ TFIIDare listed below:
9aaTADs mediate p53 interaction with general coactivators - TAF9, CBP/p300 (all four domains KIX, TAZ1, TAZ2 and IBiD), GCN5 and PC4, regulatory protein MDM2 and replication protein A (RPA).
Mutations that deactivate p53 in cancer usually occur in the DBD. Most of these mutations account for the destruction of the ability of protein to bind to its target DNA sequences, and thus prevent transcriptional activation of these genes. Mutations in the OD of p53 molecule dimerise withÂ wild-typeÂ p53, and prevent them from activating transcription. Therefore, OD mutations have a dominant negative effect on the functioning of p53. 
P53 PATHWAY AND ITS REGULATION
p53 plays a significant role in apoptosis, genomic stability, and inhibition ofÂ angiogenesis, and executes its anticancer function by the virtue of different mechanisms as follows:
activation ofÂ DNA repairÂ proteins when DNA suffers a damage.
Instigates growth arrest by holding theÂ cell cycleÂ at the G1/S regulation point, thus giving ample time to the DNA repair proteins to fix the DNA damage, and subsequent continuation of the cell cycle.
Initiation ofÂ apoptosis, the programmed cell death, if incase, the DNA damage proves to be irreparable.
p53 exists in inactive state in normal cells due to the presence of its negative regulator, mdm2. However, on DNA damage (by means including ionizing radiation, UV radiation, application of cytotoxic drugs or chemotherapeutic agents, and infectious virus) or other stresses such as heat shock, hypoxia, oxidative stress,Â osmotic shock, ribonucleotide depletion, and deregulated oncogene expression, p53 dissociates from mdm2 and this dissociation of the p53 and mdm2 complex leads to activation of p53. 
Two major events causing the activation of p53 can be highlighted as follows:
drastic increment in the half-life of the p53 protein, leading to a its accumulation in stressed cells.
aÂ conformational changeÂ forcing p53 to be activated as aÂ transcription regulatorÂ in these cells.
Phosphorylation of N-terminal domain marks the activation of p53. Several protein kinases that target phosphorylation sites present in large numbers in the N-terminal transcriptional activation domain of p53, can be roughly divided into two groups. First group comprises of protein kinases belonging to theÂ MAPKÂ family (JNK1-3, ERK1-2, p38 MAPK), which is known to respond to several types of stress including, membrane damage, oxidative stress, osmotic shock, heat shock, etc. while, the second group includes protein kinases (ATR,Â ATM,Â CHK1Â andÂ CHK2,Â DNA-PK, CAK,Â TP53RK) involved in the molecular cascade that detects and responds to several forms of DNA damage caused by genotoxic stress. Oncogenes also stimulate p53 activation, mediated by the proteinÂ p14ARF. Marked enhancement is observed in p53's sequence-specific DNA binding and transcriptional activities towards stress, due to numerous post-translational alterations within the carboxy terminus. These alterations include, phosphorylation, acetylation, and sumoylation.[69,70,71,72]
In unstressed cells, p53 is continuously degraded. A protein calledÂ Mdm2Â (also called HDM2 in humans), a product of p53, binds to p53, rendering it inactive. Mdm2 carries out the transportation of p53 from theÂ nucleusÂ to theÂ cytosol, apart from acting asÂ ubiquitin ligaseÂ and carrying out reversible attachment ofÂ ubiquitinÂ to p53 for its further degradation by theÂ proteasome. Proteosome-dependent degradation of p53 can be shunned by using ubiquitin specific proteases like,Â USP7Â (orÂ HAUSP), USP42, capable of cleaving ubiquitin off p53.Â HAUSP, which has been shown to be a better binding partner to Mdm2 than p53 in unstressed cells, is mainly localized in the nucleus, though a fraction of it have been found in the cytoplasm and mitochondria too.  USP10 located in the cytoplasm in unstressed cells also performs the same function of reversing the ubiquitination of Mdm2. On DNA damage, USP10 translocates to the nucleus and executes its activity without any interaction with Mdm2.
On activation, p53 may either account for cell-cycle arrest for repairing the DNA damage or it may carry out apoptosis to discard the damaged cells. Active p53 binds to DNA and activates several genes including, microRNA miR-34a,Â WAF1/CIP1 encoding forÂ p21Â and hundreds of other down-stream genes, to express themselves.  p21 (WAF1) binds to theÂ G1-S/CDKÂ (CDK2) and S/CDK complexes, essential molecules for the G1/S transitionÂ in the cell cycle. p21(WAF1) is when gets associated with CDK2, the cell fails to progress into the next stage of cell division. It is important to note that, a mutant p53 will not bind to DNA in an effective manner, and, as a result, the p21 protein will not be available to act as the "stop signal" for cell division.
Some of the above-mentioned protein kinases phosphorylate the N-terminal end of p53, causing the disruption of Mdm2-p53 binding. This is then followed by recruitment of other proteins like, Pin1, to induce a conformational change in p53, preventing the Mdm2-p53 binding even more. Phosphorylation of the N-terminal end allows for binding of transcriptional coactivators, likeÂ p300Â orÂ PCAF, which are essential for the acetylation of the carboxy-terminal end of p53. Thus, exposing the DNA binding domain of p53, and imparting it with the ability to activate or repress specific genes. On the other hand, deacetylase enzymes, such asÂ Sirt1Â andÂ Sirt7, can deacetylate p53, resulting into an inhibition of apoptosis. In the nutshell, it can be stated that p53 is a transcriptional activator, which regulates the functioning of several genes. Some important examples can be listed as follows:-
Growth arrest:Â p21, and Gadd45
DNA repair:Â p53R2.
Apoptosis:Â Bax, Apaf-1, PUMA and NoxA. 
Growth arrest:-The enzyme Cdk2, essential for the cell cycle progression into the S phase, can be inhibited by p21.Â Similarly, progression into the M phase requires Cdc2 which can be inhibited by p21, or GADD45. p53 by regulating the expression of these inhibitory proteins induces growth arrest.
Apoptosis:-p53 activates the expression of Apaf1 and Bax. Bax stimulates the release of cytochrome c, which alongwith Apaf1, acts as the binding site for Caspase 9. Caspase 9 induces apoptosis. Thus, p53 contributes to apoptosis. 
ROLE IN DISEASE
It is obvious that, tumor suppression ability will be severely jolted if theÂ TP53Â gene is damaged. Chemicals,Â radiation, viruses or other mutagens, may damage the TP53 gene, thus increasing the probability of uncontrolled division of cells, if any oncogenic mutation enters in the genetic make-up of an individual. A disease known asÂ Li-Fraumeni syndrome, exhibits one such situation where tumors develop early during adulthood due to inheritance of only one functional copy of theÂ TP53Â gene. More than 50 percent ofÂ humanÂ tumorsÂ are caused due to mutationÂ orÂ deletionÂ of theÂ TP53Â gene.Â
Approximately, 95% of TP53 mutations have their roots in the DNA binding domain, reflecting the fact that transcriptional activation is a key role exercised by the gene. Majority of these mutations include a single amino acid change in the core domains, indicating point mutations.  These point mutations have been classified into structural and DNA contact; where former can destabilize p53 protein, while the latter class directly interferes with residues involved in DNA binding.
Hence, endogenousÂ p53 functioning is an important cog in the wheel, inorder to combat tumor growth.Â Also, the understanding that, an excess amount of p53 may prove to be a boon, was thrashed by the fact that, the excess amount can actually cause premature aging. On the other hand, Loss of p53 creates genomic instability, which most often results in having a chromosome number that is not an exact multiple of the haploid number, a condition known as,Â aneuploidy. In certain cases, TP53 gene is not mutated, but the p53 pathway is disturbed. One such example of destabilizing p53 pathway is increased expression of mdm2 and mdm4, the negative regulators of p53.[49,50] Also, deletion or epigenetic inactivation of ARF, a negative regulator of mdm2, and known as p14ARF in human beings, accounts for destabilization of p53 pathway.[47,48]
Apart from the gene, even the protein expressed by TP53 can get affected leading to abnormal conditions. Pathogen, human papillomavirusÂ (HPV), encodes a protein, E6, which when binds with the p53 protein, causes its inactivation. This, in conjunction with the inactivation of another cell cycle regulator,Â pRb, by the HPV protein E7, allows for repeated cell division manifested in the clinical disease ofÂ warts.
Mechanism of inactivating p53
Effect of inactivation
Amino-acid changing mutation in the DNA- binding domain
Prevents p53 from binding to specific DNA sequences and activating the adjacent genes
Colon, breast, lung, bladder, brain, pancreas, stomach, oesophagus, and many others
Deletion of the carboxy-terminal domain
Prevents the formation of tetramers of p53
Occasional tumours at many different sites
Multiplication of the MDM2 gene in the genome
Extra MDM2 stimulates the degradation of p53
Products of viral oncogenes bind to and inactivate p53 in the cell, in some cases stimulating p53 degradation
cervix, liver, lymphomas
Mislocalization of p53 to the cytoplasm, outside the nucleus
Lack of p53 function(p53 functions only in the nucleus)
More than 50% cancers involve mutations in TP53 gene, this itself underlines the fact that TP53 gene or even p53 protein can provide a link to treat cancer in many cases. Hence, targeting TP53 or p53 is important clinically.
Loss of potency of TP53 has led to the occurrence of many cancers. Hence, restoration of p53 functioning by replacing the mutant gene with a functional wild-type copy, seemed to be an exciting approach towards the targeting of p53. This exciting approach is utilised and executed by Gene therapy, which in turn, depends upon the efficient delivery of the wild-type TP53 into tumor cells in vivo. Scientists have also proposed various in vitro strategies to restore the tumour suppressing function of p53 in cancer cells.
TP53-gene therapy mediated by Retrovirus
Retroviruses, by the virtue of their unavoidable qualities of getting integrated in a stable form into the genome of infected cells and requiring cell division for the transduction, pose to be an obvious candidates for gene therapy. Retrovirus-mediated gene transfer of the wild-type TP53 gene into both human lung tumor cell lines and xenograft models has been shown to inhibit the tumor cell growth[78-80]. So far, no molecule has induced biological response, but it is believed that some may prove to be lead compounds for more biologically active agents, when processed further. A promising target for anti-cancer drugs is the molecular chaperone Hsp90, which interacts with p53 in vivo.
TP53-gene therapy mediated by Adenovirus
Unlike retrovirus, adenovirus effect is not limited to actively proliferating cells. Hence, these large, doublestranded DNA viruses capable of high transduction efficiency, form a second strategy to TP53 gene replacement therapy.. Adenoviruses, by secreting certain proteins, compel the host to replicate them. Due to their inability of not getting integrated into the genome, adenoviruses exhibit no risk of insertional mutagenesis. In the 1960s, oral adenoviral vaccines were given to thousands of military recruits without increase in cancer risk.
Killing p53-deficient cells
This approach involves, the introduction of genetically modified viruses that exploits the advantage of dysfunctional p53 in cancer cells to selectively kill them. Adenoviruses infect quiescent cells and induce them to enter the S phase of the cell cycle so that viral DNA replication can proceed.
ONYX-015 (dl1520, CI-1042) is a modified form of adenoviruses, obtained from a virus that expresses the early region protein, E1B, which binds to p53 and inactivates the same. In ONYX-015, E1B region has been deleted. P53 suppression is necessary for the virus to replicate, hence it selectively replicates in p53-deficient cancer cells but not in normal cells. It was hoped that the viruses would select tumour cells, replicate and spread to other surrounding malignant tissue thus increasing distribution and efficacy. However, clinical trials of ONYX-015 have been unsatisfactory, except when the virus was used in combination with chemotherapy. One of the reasons for the disappointing results of the clinical trials can be the fact that E1B has other functions which are vital to the virus, or due to extensive fibrotic tissue causing hinderance to virus distribution around the tumour.
Modification of p53 protein functions
Accumulation of wild-type p53 can be achieved by disrupting the negative regulation by mdm-2. Mdm-2 gene contains a p53-responsive element within itself to which p53 binds, thus transcriptionally activating the protein mdm-2. Mdm-2 binds to the N-terminus of p53,and prevents p53 from interacting with the transcriptional machinery and induces its degradation by the proteasome. In 1997, Bottger et al. designed a synthetic mdm-2-binding miniprotein that specifically targets the p53-binding site.Certain synthetic polyamines analogs have also been shown to activate p53 function in a number of cultured cell lines[84,85].
Pifithrin, a synthetic compound, rescues p53 cells from apoptotic death induced by irradiation and various cytotoxic drugs including doxorubicin, etoposide, paclitaxel and ara-C. Thus, pifithrin may be used to suppress the side effects of radiation therapy or chemotherapy in cancer patients. However, pifithrin could act as an activator of the p53 pathway promoting doxorubicin-induced apoptosis in mouse epidermal JB6 C141 cells.
Re-activation of wt-p53 activity in mutant p53
Some mutants totally lose wild-type p53 function, while some are not associated with irreversible loss of wild-type activity. The sequence-specific DNA-binding, a key biochemical activity of p53, is altered by mutation. This activity is regulated by two C-terminal domains (residues 325-363) and negative control of DNA-binding (residues 363 393). Inhibition of the latter domain is crucial for high-affinity binding to DNA. Several experimental studies have shown that it is possible to target this domain specifically with peptides or proteins that neutralize the negative regulation exerted by the extreme C-terminus.
p53 deficient cells when subjected to in-vitro introduction of p53, exhibits a rapid death of cancer cells or prevention of further cell division. Apart from guarding the cell from various stress signals other functions of p53 in suppressing the tumours have been identified. These include, direct effects on survival proteins in the mitochondria[65,66], regulation of microRNA processing , and involvement in dNA repair pathways
Strategies and mechanisms for small molecules that target the p53 pathway:-
Mechanism of action
Stage in clinical testing
Reactivate mutant p53
Protein thermal stability
Activate wild-type p53
SIRT1 and SIRT2 inhibition
Phase I (Elactocin; withdrawn)
RPL11 and RPL5 release
Cyclotherapy (temporal combination of p53 activator and mitotic inhibitor)
BI-2536 (PLK1 inhibitor)â€¡
Phase I/Phase IÂ§
VX680 (Aurora inhibitor||)â€¡
Phase I/Phase IÂ§
Taxol (Tubulin binding)â€¡
*p53 activator. â€¡ Mitotic inhibitor. Â§Combinations are not in trial together or have been approved together. ||d.L.P., unpublished
observations. CRM1, exportin 1; PLK1, polo-like kinase 1; RITA, reactivation of p53 and induction of tumour cell apoptosis; RPL, ribosomal protein L; SIRT, sirtuin.
According to a recent report, combination of CDK inhibitors (Roscovitine and DRB) and nutlin-3 showed synergistic effect not only in the activation of p53, but also in the apoptosis of p53 wild-type tumor cells.
Apart from retaining the non-genotoxic nature characteristic of the individual compounds, the combination also confirms the concept that combinations of low doses of individual compounds which are not sufficiently dose potent on their own, are effective in inducing the desired outputs. However, determination of a fixed ratio of the compounds and formulating them so as to work optimally together taking into account the variable PK and PD properties of the individual molecules, is a barrier in designing these drug combinations.
Marked increment in the growth of tumors in an immune-suppressed individual indicates a possible role of weakened immune system in cancer. Thus, the immune system can be extremely effective in controlling tumor growth. In model systems using virally transformed cells, small numbers of cytotoxic T cells can completely control tumor growth by recognizing the peptides displayed on the surface of the tumor cell through the MHC system.
However, due to absence of 'tumor specific antigens', tumor immunity looks ineffective against continuosly expanding tumors in man. Inorder to establish tumor-specificity, it is important that immune system distinguishes self from nonself, effectively. This can be achieved with the help of regulatory T cells in the periphery.
p53, present in the tumor cells may be considered "nonself" or tumor specific because the tumor specific mutations present in the p53 protein may alter its antigenicity, if the mutations occur in a region of the protein that can be presented as an epitope to the T cell; and also because of its universal nature, the p53 protein in tumor cells accumulates to high levels implying that it is subject to different processes of degradation, which in turn may lead to the production of different peptide fragments to those that result from the processing of p53 in normal tissue cells, thus easy and specific identification by T- cells. Currently a variety of p53-based vaccines have proved effective in animal models and are now undergoing trial in man. Key p53 peptide epitopes have been discovered[75,76]
CONCLUSION & FUTURE OF P53-
An age-old thinking that cells accumulates a succession of genetic modifications accompanied
by an increase in the aggressiveness of the tumour needs to be disbelieved now. p53 gene alone might be implicated in both control of proliferation, and control of cell migration. Consequently, no specific genetic changes can be exclusively associated with invasiveness, due to their participation in the formation of primary tumours.
The question whether the internal domains of p53 which are important for its function, overlap with those necessary for its anti-proliferative properties is yet to be answered. It would certainly provide an insight into the manner in which p53 essays its two roles, anti-proliferator and cell migration regulator. Also, further studies are necessary to comprehend and confirm whether the role of p53 in cell migration influences metastatic development in human cancers. It will ascertain the relative contributions of each of the functional properties of p53, i.e. control of cell cycle, apoptosis and cell migration, in tumorigenesis. More work needs to be done to uncover the excitement surrounding the existence of gene exclusivity associated with primary tumour formation with no effect on cell migration. The outcome of these studies can provide a novel and promising anti-cancer therapeutic approach.